



EGeen RNA Program Country Card – Latvia



Latvia Overview



- Population: 1.98 million
- Five Largest Cities: Riga, Daugavpils, Liepaja, Jelgava, Jurmala
- Language: Latvian
- EU Member: Yes (2004)
- Govt Type: Parliamentary Republic
- Govt. Admin.: 110 Municipalities + 9 republican cities
- Health System: National Health System (govt.funded) + user charges

Clinical Trial Network / Comments



- HC Sites: 67 hospitals, >30+ clinics, 3.4 beds per 1000
- HC Splits: 84% public / 16% private; 32% inpatient / 68% outpatient
- Investigators: ICH GCP experienced, high quality, motivated, excellent data
- CRAs: Physicians, biologists, nurses; good relations with investigators
- High level cardiovascular disease
- Highest incidence rate of ovarian cancer in the world


EGeen Clinical Trial Support



- Full range of clinical trial services
- Patient recruitment, clinical monitoring, data management, biostatistics, regulatory
- Pharmacovigilance, project management, ethics review, quality assurance
- EU Qualified Person (QP) assistance to obtain EU GMP certificate for manufacturing reqs.
- Cost-effective EU / EE / non-EU importation partnerships and local IMP logistics
- Institutional relationships to proactively obtain contract approvals prior to regulatory filings as needed



Latvia – Clinical Trail Process Overview



Latvia Approval Process Highlights



- Qualified Person (QP) must be identified and registered prior to approval process beginning
- CTA site contracts can be negotiated during RA, CEC and LEC approval process, saving time
- RA and CEC approvals can begin concurrently, saving time
- All major submission documents need to be in Latvian language **NOTE**
- No LEC submission required **NOTE**
- All major approval processes can run in parallel, saving time
- Import / Export license required only if IMP is outside EU **NOTE**
- Summary: Time from QP ID to Importation of IMP estimated at **16 weeks**

Note: Summary time total is an estimated average of trial complexity